Characterization of the serotonin 2A receptor selective PET tracer (R)-[18F]MH.MZ in the human brain
Purpose The serotonin receptor subtype 2A antagonist (5-HT 2A R) (R)-[ 18 F]MH.MZ has in preclinical studies been identified as a promising PET imaging agent for quantification of cerebral 5-HT 2A Rs. It displays a very similar selectivity profile as [ 11 C]MDL 100907, one of the most selective comp...
Gespeichert in:
Veröffentlicht in: | European journal of nuclear medicine and molecular imaging 2020-02, Vol.47 (2), p.355-365 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Purpose
The serotonin receptor subtype 2A antagonist (5-HT
2A
R) (R)-[
18
F]MH.MZ has in preclinical studies been identified as a promising PET imaging agent for quantification of cerebral 5-HT
2A
Rs. It displays a very similar selectivity profile as [
11
C]MDL 100907, one of the most selective compounds identified thus far for the 5-HT
2A
R. As [
11
C]MDL 100907, (R)-[
18
F]MH.MZ also displays slow brain kinetics in various animal models; however, the half-life of fluorine-18 allows for long scan times and consequently, a more precise determination of 5-HT
2A
R binding could still be feasible. In this study, we aimed to evaluate the potential of (R)-[
18
F]MH.MZ PET to image and quantify the 5-HT
2A
R in the human brain in vivo.
Methods
Nine healthy volunteers underwent (R)-[
18
F]MH.MZ PET at baseline and four out of these also received a second PET scan, after ketanserin pretreatment. Regional time–activity curves of 17 brain regions were analyzed before and after pretreatment. We also investigated radiometabolism, time-dependent stability of outcomes measures, specificity of (R)-[
18
F]MH.MZ 5-HT
2A
R binding, and performance of different kinetic modeling approaches.
Results
Highest uptake was determined in 5-HT
2A
R rich regions with a BP
ND
of approximately 1.5 in cortex regions. No radiometabolism was observed. 1TCM and 2TCM resulted in similar outcome measure, whereas reference tissue models resulted in a small, but predictable bias. (R)-[
18
F]MH.MZ binding conformed to the known distribution of 5-HT
2A
R and could be blocked by pretreatment with ketanserin. Moreover, outcomes measures were stable after 100–110 min.
Conclusion
(R)-[
18
F]MH.MZ is a suitable PET tracer to image and quantify the 5-HT
2A
R system in humans. In comparison with [
11
C]MDL 100907, faster and more precise outcome measure could be obtained using (R)-[
18
F]MH.MZ. We believe that (R)-[
18
F]MH.MZ has the potential to become the antagonist radiotracer of choice to investigate the human 5-HT
2A
R system. |
---|---|
ISSN: | 1619-7070 1619-7089 |
DOI: | 10.1007/s00259-019-04527-w |